Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cuneo
Clinical trial register · Italy

Clinical Trials in Cuneo, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 2843 Bologna 1305 Roma 1274 Naples 984 Rome 967
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fondazione Italiana Linfomi - ETS5 Consorzio Oncotech3 Gruppo Oncologico Italiano di Ricerca Clinica3 European Myeloma Network B.V.2 AstraZeneca2
Site location
Milan2843 Bologna1305 Roma1274 Naples984 Rome967
All 489 locations
Target enrolment
to

Trials with a site in Cuneo

52 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
By invitation
Novo Nordisk A/S
Observational
214
Pescara, San Giovanni in Fiore (CS), Marano Di Napoli (NA), Rome, Milan, Cuneo, Catania, Bolzano
2026-05-28
Not yet open
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2
108
Bologna, Cuneo, Meldola, Cona, Lido di Camaiore, Lucca, Mantua, Pisa
2026-05
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Bergamo, Bologna, Cuneo, Florence, Palermo, Pavia, Pescara, Roma
2026-02-08
Not yet open
PONDER: Pelvic Peritonectomy in Early Stage Ovarian Tumors
NCT07271914Early Stage Ovarian Tumors, Peritoneal Carcinosis
Ospedale Santa Croce-Carle Cuneo
Not applicable
390
Cuneo
2026-02
Not yet open
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2
270
Arezzo, Aviano, Bologna, Brescia, Catania, Cuneo, Florence, Genova
2026-01-31
Recruiting
Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Hospitalizations
NCT06846879Quality of Care, Evaluation, Emergency Department, Appropriateness
Mario Negri Institute for Pharmacological Research
Observational
240,000
Alessandria, Cuneo, Novara, Novi Ligure, Orbassano, Rivoli, Torino
2026-01-05
Recruiting
European Myeloma Network B.V.
Phase 3
1,000
Ancona, Cuneo, Florence, Genova, Legnano, Meldola, Milan, Reggio
2025-12-23
Recruiting
Azienda Ospedaliero-Universitaria di Parma
Not applicable
310
Parma, Bologna, Cuneo, Milan, Udine
2025-10-07
Recruiting
AstraZeneca
Phase 2
987
Busto Arsizio, Cuneo, Ferrara, Milan, Monza, Naples, Pavia, Roma
2025-06-27
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Rozzano, Acquaviva delle Fonti, Bergamo, Cuneo, Livorno, Milan, Naples, Pavia
2025-06-19
Not yet open
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
Observational
600
Orbassano, Bari, Bologna, Cagliari, Cuneo, Ferrara, Florence, Genova
2025-06-01
Recruiting
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
NCT05815927Oligometastatic Squamous Cell Carcinoma of the Head and Neck
DrugPembrolizumab
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
200
Bologna, Cuneo, Florence, Milan, Naples, Ravenna, Rome
2025-05-23
Recruiting
BRCA Mutation Carriers' Platform a Multicenter Study
NCT07253051BRCA1 Mutation, BRCA2 Mutation
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Observational
10,000
Avellino, Aviano, Bari, Bergamo, Catania, Cuneo, Enna, Florence
2025-04-05
Recruiting
PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)
NCT07089550PSMA Positive Tumors or Tumor Tissues, Prostate Cancer Metastatic
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
1,300
Bologna, Cuneo, Genova, Messina
2025-04-02
Not yet open
Consorzio Oncotech
Observational
1,000
Avellino, Bergamo, Bologna, Brescia, Termoli, Caserta, Cuneo, Ferrara
2025-03
Recruiting
Study on Plasmablastic Lymphoma Patients
NCT06781359Plasmablastic Lymphoma
Fondazione Italiana Linfomi - ETS
Observational
200
Aviano, Ascoli Piceno, Brescia, Cuneo, Florence, Milan, Monza, Novara
2025-02-14
Recruiting
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2
142
Aviano (PN), Bari, Bologna, Carpi, Cremona, Cuneo, Florence, Lido di Camaiore
2025-01-24
Recruiting
Basilea Pharmaceutica
Phase 3
450
Cuneo, Genoa, Milan, Modena, Pavia, Pisa, Siena, Trieste
2024-12-11
By invitation
Mario Stirpe
Observational
96
Acquaviva delle Fonti, Altamura, Cuneo, Florence, Piacenza, Sassari, Venezia, Vercelli
2024-11-28
Active, closed
Fondazione Italiana Linfomi - ETS
Observational
241
Milan, Aviano, Bergamo, Bologna, Brescia, Cagliari, Cuneo, Florence
2024-10-30
Active, closed
Regeneron Pharmaceuticals
Phase 2
151
Cuneo, Ferrara, Milan, Naples, Novara, Pisa, Rome, Taormina
2024-09-18
Recruiting
Consorzio Oncotech
Observational
300
Bari, Bologna, Cuneo, Catania, Meldola, Florence, Genova, Monza
2024-09-13
Active, closed
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
DrugsABP 234·Pembrolizumab
Amgen
Phase 3
163
Cona, Cuneo, Florence, Lucca, Monserrato, Naples, Peschiera del Garda, Ravenna
2024-09-12
Recruiting
San Luigi Gonzaga Hospital
Not applicable
360
Aosta, Biella, Cuneo, Cona, Genova, Rivoli, Trapani, Orbassano
2024-09-01
Recruiting
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
NCT06459024Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Observational
4,000
Bologna, Brindisi, Brescia, Cuneo, Como, Cremona, Ferrara, Genova
2024-06-28
Recruiting
A Registry-study of ELZONRIS in Participants With BPDCN
NCT07785154Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
DrugTagraxofusp
Stemline Therapeutics, Inc.
Observational
80
Alessandria, Bologna, Catania, Cuneo, Ferrara, Florence, Genova, Milan
2024-06-26
Active, closed
Merus B.V.
Phase 3
621
Brescia, Cuneo, Milan, Naples, Roma, Rozzano
2024-06-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Bari, Aviano, Udine, Milan, Naples, Perugia, Catania, Cuneo
2023-12-06
Recruiting
Gruppo Oncologico del Nord-Ovest
Phase 2/3
300
Ancona, Bergamo, Bologna, Brescia, Cuneo, Meldola, Milan, Modena
2023-11-07
Recruiting
Fondazione Italiana Linfomi - ETS
Observational
654
Alessandria, Biella, Brescia, Catania, Cuneo, Florence, Genova, Meldola
2023-09-19
Recruiting
The Lymphoma Academic Research Organisation
Phase 3
260
Bologna, Castelfranco Veneto, Cuneo, Latina, Lecce, Milan, Modena, Pavia
2023-09-05
Recruiting
Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure
NCT06918912Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), B-Cell Lymphoma Treatment, Relapsed or Refractory Lymphoma
DrugLoncastuximab Tesirine
Istituto Clinico Humanitas
Phase 2
50
Alessandria, Bologna, Cuneo, Milan, Rozzano, Roma
2023-06-16
Not yet open
Reverse T-stenting and Minimal Protrusion With External Minicrush for Treatment of Complex Coronary Bifurcation
NCT05782738Coronary Artery Disease, Coronary Stenosis, Coronary Disease
San Luigi Gonzaga Hospital
Not applicable
361
Cirié, Moncalieri, Alessandria, Cuneo, Turin
2023-06-01
Active, closed
Fondazione Italiana Linfomi - ETS
Observational
160
Milan, Siena, Aviano, Brescia, Cuneo, Florence, Novara, Padova
2023-02-08
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,564
Ancona, Naples, Meldola, Milan, Bari, Cuneo, Perugia, Rome
2023-01-16
Recruiting
Universita di Verona
Not applicable
1,030
Cuneo, Reggio Emilia, Verona
2023-01-16
Active, closed
Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia
NCT07232953Acute Myeloid Leukaemia (AML), Hematopoietic Stem Cell Transplant (HSCT)
DrugsTreosulfan·Fludarabine
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2
82
Reggio Calabria, Naples, Modena, Udine, Brescia, Milan, Cuneo, Ancona
2022-11-10
Active, closed
Pierre Fabre Medicament
Phase 3
815
Meldola, Taormina, Naples, Aviano, Bari, Bergamo, Cuneo, Genova
2022-05-02
Active, closed
Fondazione Italiana Linfomi - ETS
Phase 2
49
Brescia, Alessandria, Cuneo, Florence, Genova, Milan, Naples, Novara
2022-03-21
Active, closed
Ascendis Pharma Oncology Division A/S
Phase 1/2
320
Cuneo, Florence, Grosseto, Lido di Camaiore, Livorno, Meldola, Milan, Modena
2022-01-11
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Bologna, Catanzaro, Cona, Cuneo, Florence, Meldola, Milan, Modena
2021-09-20
Active, closed
Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse
NCT04475731Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse
DrugPonatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2
67
Ancona, Ascoli Piceno, Avellino, Bari, Bergamo, Bologna, Brescia, Cuneo
2021-05-04
Active, closed
University of Zurich
Not applicable
986
Cuneo, Genova, Palermo, Turin
2020-09-30
Active, closed
European Myeloma Network B.V.
Phase 3
302
Ancona, Bari, Bologna, Brescia, Cuneo, Florence, Novara, Pavia
2020-09-25
Active, closed
Gruppo Italiano Trapianto di Midollo Osseo
Phase 2
120
Cagliari, Naples, Ancona, Bari, Bologna, Brescia, Cuneo, Florence
2019-12-06
Active, closed
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2
76
Ancona, Ascoli Piceno, Bergamo, Bologna, Bolzano, Brescia, Cuneo, Genova
2019-10-30
Active, closed
AstraZeneca
Phase 3
140
Cuneo, Florence, Milan, Naples, Roma, Torino
2019-10-29
Active, closed
Consorzio Oncotech
Observational
600
Aviano, Bari, Bergamo, Brindisi, Chieti, Como, Cuneo, Florence
2019-10-24
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed
Genmab
Phase 1/2
350
Brescia, Cuneo, Milan, Rozzano
2019-09-17
Recruiting
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
NCT03328078Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
DrugsEmavusertib·Ibrutinib
Curis, Inc.
Phase 1/2
152
Cuneo, Florence, Meldola, Milan
2017-12-28
Recruiting
Fosfomycin I.v. for Treatment of Severely Infected Patients
NCT02979951Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections
Infectopharm Arzneimittel GmbH
Observational
1,000
Bari, Cuneo, Genova, Milan, Palermo, Rome, Torino, Udine
2016-12
Recruiting
PREgnancy and FERtility Registry
NCT02895165Breast Neoplasms, Pregnancy, Fertility Preservation
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Observational
1,000
Asti, Brindisi, Monserrato, Cuneo, Cona, Genoa, Lecce, Lido di Camaiore
2012-11
Rows per page Showing 1–52 of 52
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 October 2026. https://priyalifescience.com/clinical-trials-italy/city/cuneo

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 52 of those studies with a site in Cuneo.

How many clinical trials are recruiting in Cuneo?

23 of the 52 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 6 have not yet opened recruitment, 21 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cuneo), 52 studies
PhaseStudiesRecruitingShare
Observational171032.7%
Phase 213425%
Phase 312423.1%
Not applicable6311.5%
Phase 1/2315.8%
Phase 2/3111.9%

Most active sponsors

Lead sponsors with the most studies (Cuneo)
Lead sponsorStudiesRecruiting
Fondazione Italiana Linfomi - ETS52
Consorzio Oncotech31
Gruppo Oncologico Italiano di Ricerca Clinica31
AstraZeneca21
European Myeloma Network B.V.21
Gruppo Italiano Malattie EMatologiche dell'Adulto20
Regeneron Pharmaceuticals20
San Luigi Gonzaga Hospital21
Amgen10
Ascendis Pharma Oncology Division A/S10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.